title: Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study.
abstract: OBJECTIVE
  To assess whether methylcobalamin and alpha lipoic acid (ALA) added to pregabalin provide additional benefit compared to pregabalin alone in type 2 diabetes mellitus associated peripheral neuropathy.
  
  
  METHODS
  An open label, randomized, controlled parallel-group pilot study.
  
  
  METHODS
  Thirty adult patients with type 2 diabetes mellitus with symptoms of peripheral neuropathy for ≥6 months were randomized to receive pregabalin 75 mg, methylcobalamin 750 μg, and ALA 100 mg (PMA, n = 15); or pregabalin 75 mg (PG, n = 15) for 12 weeks. Assessment variables were numeric rating scale (NRS), sleep interference scores (SIS), response rate to pain, and global assessment for the usefulness of therapy. The nerve conduction velocity was assessed for sensory and motor nerves. Safety assessment included adverse events reported by the patients, clinical laboratory, and general medical, neurological examinations.
  
  
  METHODS
  Efficacy analyses were done on per-protocol (PP) population, whereas safety analyses were done on intent-to-treat (ITT) population.
  
  
  RESULTS
  Significant improvement was seen in pain and sleep interference in both groups. Mean nerve conduction velocity of left common peroneal nerve (CPN) showed significant improvement in PMA group at week 12 compared to baseline (P = 0.018). For right CPN both groups showed significant improvement. (PMA, P = 0.002, PG, P = 0.007). For sensory testing, at week 12, right superficial peroneal nerve showed reduction in nerve conduction velocity in PG group compared to baseline (P = 0.043).
  
  
  CONCLUSIONS
  Methylcobalamine, ALA and pregabalin combination provides pain relief and improves sleep interference. Addition of methylcobalamin and ALA to pregabalin improves the nerve function. Due to small sample size, most of the efficacy parameters could not reach significant difference between groups; hence benefit of the 3-drug-combimation should be interpreted with reservation.
authors.affiliation: The Brain Spine and Nerve Centre, Chennai, Tamil Nadu, India.
authors.forename: D
authors.initials: D
authors.lastname: Vasudevan
authors.affiliation: Medical Services, Abbott Healthcare Pvt Limited, Mumbai, Maharashtra, India.
authors.forename: Manoj M
authors.initials: MM
authors.lastname: Naik
authors.affiliation: Medical Services, Abbott Healthcare Pvt Limited, Mumbai, Maharashtra, India.
authors.forename: Qayum I
authors.initials: QI
authors.lastname: Mukaddam
keywords: Alpha lipoic acid (ALA); diabetic neuropathy; methylcobalamin; pregabalin
references.citation: Neurology. 1998 Jun;50(6):1842-6
references.pmid: 9633738
references.citation: Diabetes Res Clin Pract. 2000 Feb;47(2):123-8
references.pmid: 10670912
references.citation: Eur J Pharmacol. 1993 Sep 7;241(1):1-6
references.pmid: 7901032
references.citation: Diabetologia. 1993 Feb;36(2):150-4
references.pmid: 8458529
references.citation: Invest Ophthalmol Vis Sci. 1997 Apr;38(5):848-54
references.pmid: 9112980
references.citation: Methods Find Exp Clin Pharmacol. 1995 Oct;17(8):539-44
references.pmid: 8749227
references.citation: Exp Clin Endocrinol Diabetes. 1999;107(7):421-30
references.pmid: 10595592
references.citation: Diabetes Care. 2006 Nov;29(11):2365-70
references.pmid: 17065669
references.citation: Diabetes Care. 2004 Jan;27 Suppl 1:S5-S10
references.pmid: 14693921
references.citation: Med Clin North Am. 1998 Jul;82(4):909-29
references.pmid: 9706126
references.citation: Diabetes Care. 2005 Apr;28(4):956-62
references.pmid: 15793206
references.citation: Acta Neurol Taiwan. 2005 Jun;14(2):48-54
references.pmid: 16008162
references.citation: J Neurol Sci. 1995 Mar;129(1):62-8
references.pmid: 7751847
references.citation: Endocrinol Metab Clin North Am. 1996 Jun;25(2):325-59
references.pmid: 8799703
references.citation: Neurology. 1999 Aug 11;53(3):580-91
references.pmid: 10449124
references.citation: Neurosci Lett. 1994 Mar 28;170(1):195-7
references.pmid: 8041506
references.citation: Gen Physiol Biophys. 2010 Mar;29(1):50-8
references.pmid: 20371880
references.citation: Rev Diabet Stud. 2009 Winter;6(4):230-6
references.pmid: 20043035
references.citation: Diabetes Care. 2011 Sep;34(9):2054-60
references.pmid: 21775755